rs1064794055
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.2028_2029delAA(p.Ser677fs) variant causes a frameshift change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 5 Pathogenic:1
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
not provided Pathogenic:1
This pathogenic variant is denoted MSH6 c.2028_2029delAA at the cDNA level and p.Ser677Ter (S677X) at the protein level. The substitution creates a nonsense variant, which changes a Serine to a premature stop codon (AGT>TGA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant was observed in at least one individual with colorectal cancer, whose tumor exhibited microsatellite instability and absence of MSH6 protein on immunohistochemistry (Graham 2015). This variant is considered pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 419704). This premature translational stop signal has been observed in individual(s) with colorectal cancer (PMID: 26099011). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser677*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.2028_2029delAA pathogenic mutation, located in coding exon 4 of the MSH6 gene, results from a deletion of two nucleotides at nucleotide positions 2028 to 2029, causing a translational frameshift with a predicted alternate stop codon (p.S677*). This mutation has been reported in a female patient with a colon tumor that was MSH6 negative by IHC analysis (Graham RP et al. Am. J. Surg. Pathol. 2015 Oct;39:1370-6). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Endometrial carcinoma Pathogenic:1
The MSH6 p.Ser677* variant was identified in the literature however the frequency of this variant in an affected population was not provided. The variant was also identified in ClinVar (classified as pathogenic by GeneDx and Invitae). The variant was not identified in dbSNP, GeneInsight-COGR, Cosmic, UMD-LSDB, Zhejiang University Database, Mismatch Repair Genes Variant Database, or Insight Hereditary Tumors databases. The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The c.2028_2029del variant leads to a premature stop codon at position 677 which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the MSH6 gene are an established mechanism of disease in MSH6 associated cancers and is the type of variant expected to cause the disorder. The variant occurs outside of the splicing consensus sequence and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In addition, review of MMR immunohistochemistry on the mutation revealed complete loss of MSH6 (Graham 2015). In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at